Shares of 4d Pharma PLC (LON: DDDD) are trading above a crucial support level, indicating that the recent selloff after its NASDAQ dual-listing might finally be over.
The British biotech company that develops novel drugs based on live biotherapeutics from the microbiome has seen its shares fall after the much-awaited NASDAQ dual-listing in a classic “buy the rumour, sell the news” scenario.
The shares might have recently hit a floor around the 100p level and have since bounced off the level, signalling that the selloff might finally be over. Still, a single bounce off the level is not a guarantee that the downtrend is over; the level must hold over the coming days.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The last time we covered 4d Pharma shares, we said that major positive announcements could provide the right momentum for a rally, and we are yet to get such news.
The company’s latest announcement was the issuance of instructions to its UK shareholders who want to convert their AIM-listed shares into NASDAQ ADSs. The conversion is being handled by J.P.Morgan and is free up to 22 March 2022.
Investors interested in buying 4d Pharma shares could find the current price quite appealing given the biotech company’s strong financial position following its NASDAQ dual-listing, which are coincided with a $24.03 million capital raise.
Duncan Peyton, 4D pharma’s CEO, said: “The additional funds that these combined activities deliver will enable 4D pharma to continue the rapid pace of development on our pipeline of Live Biotherapeutics, including lead oncology program, MRx0518 targeting a range of cancers, as well as other therapeutic areas such as neurological conditions.”
Adding:
“We have a robust line up of milestones set for 2021, and with both our new US institutional support and upcoming NASDAQ listing, we look forward to providing updates from our novel, single-strain LBP programs to our expanded global audience.”
4D Pharma share price.
4D Pharma shares are trading above the 100p resistance level. Can they launch a sustained rally?
